Given the clinical potential in applying MEK inhibitors to treat various tumor types, including CRC, we sought to determine whether the GEMM signature was predictive of response to these inhibitors as determined by a publicly available study of drug sensitivity across a comprehensive collection of cancer cell lines (http://www.cancerrxgene.org), with a focus on CRC. The gene discussed is MAP2K7; the disease is neoplasm.